Skip to content

Adipokine Genetic Variations in predictingNAFLD Progression to NASH in Egyptian Patients

Genetic Variations in Adipokine to Improve Risk Prediction for NAFLD and Its Progression to NASH in Egyptian Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04561895
Enrollment
224
Registered
2020-09-24
Start date
2020-01-01
Completion date
2020-09-16
Last updated
2020-09-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NAFLD, NASH - Nonalcoholic Steatohepatitis

Keywords

Egyptian population, NAFLD, NASH, DNA extraction, liver enzymes

Brief summary

Due to the limited data concerning Egyptian population. authors aimed to investigate the differentadipokine gene polymorphism related to non alcoholic fatty liver disease incidence, prognosis and progression to steotosis and also to find different related factors including obesitu, diabetes and liver enzymes level

Interventions

investigation of DNA polymorphism in patients suffering from NAFLD

Sponsors

Elsahel teaching hospital
CollaboratorUNKNOWN
Cairo University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years

Inclusion criteria

Egyptian patients confirmed NAFLD diagnosis diabetic \-

Exclusion criteria

* Pregnancy and lactation, history of alcohol abuse (as defined by an average daily consumption of alcohol \> 30 g/day in men and \> 20 g/day women), cirrhosis, autoimmune hepatitis and other causes of liver disease (viral hepatitis, hemochromatosis, Wilson's disease), drug induced hepatitis, chronic enteropathies, Chronic kidney disease

Design outcomes

Primary

MeasureTime frameDescription
investigate adipokine dna polymorphism1 monthsto investigate adipokine gene polymorphism associated with prognosis of NAFLD patients
correlations1 monthto correlate between gene polymorphism and glycated hemoglobin, liver enzyme and obesity

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026